Christian Blank, Prof
Medical oncologist/researcher
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christian Blank, Prof as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:58 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06240143 · Intradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaThe Netherlands Cancer Institute · recruiting · Melanoma · principal investigator
- Ph3NCT04949113 · Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III MelanomaThe Netherlands Cancer Institute · active not recruiting · Malignant Melanoma Stage III · study chair
- Ph1/Ph2NCT04133948 · Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaThe Netherlands Cancer Institute · completed · Malignant Melanoma Stage III · study chair
- Ph2NCT02977052 · Optimal Neo-adjuvant Combination Scheme of Ipilimumab and NivolumabThe Netherlands Cancer Institute · unknown · Malignant Melanoma Stage III · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.